Abbott Laboratories (ABT) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Competitors, else..
 
Abbott Laboratories  (NYSE: ABT)
 

Abbott Laboratories Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ABT Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 14.46 % 14.14 % 10.18 % 10.9 %
Q / Q Revenue Growth (Q3 MRQ) 3.34 % -1.07 % -2.46 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 10 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) 3.53 % 2.69 % 2.1 % 2.61 %
Revenue 5 Year Average Growth 5.08 % 7.52 % 8.67 % 13.63 %


ABT's Growth Comparisons in III. Quarter 2026




Abbott Laboratories improved it's Revenue by 14.46% year on year in the third quarter 2026, and outpaced the 14.14% rise in the Major Pharmaceutical Preparations industry, and 10.18% improvement in the Healthcare sector. Comparing the third quarter sales growth, both Major Pharmaceutical Preparations industry and Abbott Laboratories outperformed 10.9% overall market increase.

Comparing the company's Revenue to the second quarter results, sales were higher by 3.34% . On the yearly basis, average annual sales growth for Abbott Laboratories is 5.08%, while S & P 500's including only Businesses with the third quarter 2026 earnings, average annual sales growth is 13.63% over the past five years.

ABT Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
United States
2.54 %
-
International
11.31 %
-
Established Pharmaceuticals
13.17 %
-
Established Pharmaceuticals Key Emerging Markets
12.85 %
-
Established Pharmaceuticals Other
14.24 %
-
Nutritional Products
-6.01 %
-
Nutritional Products Pediatric Nutritionals
-8.45 %
-
Nutritional Products Adult Nutritionals
-3.71 %
-
Diagnostic Products
6.13 %
-
Diagnostic Products Core Laboratory
8.07 %
-
Diagnostic Products Rapid and Molecular
-7.41 %
-
Diagnostic Products Cancer Diagnostics
-
-
Medical Devices
13.16 %
-
Medical Devices Rhythm Management
16.92 %
-
Medical Devices Electrophysiology
16.74 %
-
Medical Devices Heart Failure
14.75 %
-
Medical Devices Vascular
9.44 %
-
Medical Devices Structural Heart
8.85 %
-
Medical Devices Neuromodulation
6.58 %
-
Medical Devices Diabetes Care
13.85 %
-
United States Nutritional Products
-11.62 %
-
United States Nutritional Products Pediatric Nutritionals
-13.1 %
-
United States Nutritional Products Adult Nutritionals
-9.26 %
-
United States Diagnostic Products
3.9 %
-
United States Diagnostic Products Core Laboratory
4.52 %
-
United States Diagnostic Products Rapid and Molecular
-13.73 %
-
United States Diagnostic Products Cancer Diagnostics
-
-
United States Medical Devices
7.87 %
-
United States Medical Devices Rhythm Management
11.51 %
-
United States Medical Devices Electrophysiology
13.51 %
-
United States Medical Devices Heart Failure
11.45 %
-
United States Medical Devices Vascular
8.58 %
-
United States Medical Devices Structural Heart
-9.68 %
-
United States Medical Devices Neuromodulation
0.57 %
-
United States Medical Devices Diabetes Care
9.89 %
-
International Established Pharmaceuticals
13.17 %
-
International Established Pharmaceuticals Key Emerging Markets
12.85 %
-
International Established Pharmaceuticals Other
14.24 %
-
International Nutritional Products
-1.51 %
-
International Nutritional Products Pediatric Nutritionals
-2.43 %
-
International Nutritional Products Adult Nutritionals
-0.95 %
-
International Diagnostic Products
7.78 %
-
International Diagnostic Products Core Laboratory
9.47 %
-
International Diagnostic Products Rapid and Molecular
2.66 %
-
International Diagnostic Products Cancer Diagnostics
-
-
International Medical Devices
18 %
-
International Medical Devices Rhythm Management
22.78 %
-
International Medical Devices Electrophysiology
19.88 %
-
International Medical Devices Heart Failure
25.97 %
-
International Medical Devices Vascular
9.95 %
-
International Medical Devices Structural Heart
25.09 %
-
International Medical Devices Neuromodulation
26.92 %
-
International Medical Devices Diabetes Care
16.59 %
-
Other
-33.33 %
-
Other United States
-33.33 %
-
Total
7.78 %
-


Growth Rates of ABT's Income in the third quarter 2026


ABT Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) -33.98 % 4.19 % 11.09 % 97.6 %
Sequential Operating Income Change (Q3 MRQ) -19.79 % -23.95 % -12.21 % 48.13 %
Y / Y Operating Income Growth (Q3 TTM) -13.82 % 30.78 % 30.98 % 40.67 %
Sequential Operating Income Growth (Q3 TTM) -9.52 % -2.24 % 4.93 % 20.86 %
Operating Income 5 Year Avg. Change 8.49 % 14.12 % 10.27 % 18.8 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) -44.04 % -16.85 % -38.86 % 90.69 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) -0.86 % -26.31 % -63.27 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) -62.31 % 6.26 % 9.88 % 57.33 %
Sequential Income from Cont. Ops. Change (Q3 TTM) -11.89 % -9.98 % -4.67 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change 7.85 % 14.58 % 8.91 % -28.64 %

ABT Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) -44.04 % -17.47 % -39.2 % 90.69 %
Q / Q Net Income Growth (Q3 MRQ) -0.86 % 21.94 % 11.78 % 27.07 %
Y / Y Net Income Change (Q3 TTM) -66.37 % 5.06 % 15.43 % 57.33 %
Sequential Net Income Change (Q3 TTM) -13.35 % -10.2 % -6.73 % 18.65 %
Net Income 5 Year Avg. Growth 7.74 % 14.16 % 9.09 % 23.95 %

ABT's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) -43.62 % -31.09 % -38.86 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) 0 % -35.27 % -63.27 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) -66.29 % - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) -13.14 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth 8.24 % -0.46 % 8.91 % -28.64 %



ABT EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) -43.62 % -31.6 % -39.2 % -28.64 %
Q / Q EPS Net Growth (Q3 MRQ) 0 % 7.1 % 11.78 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) -13.18 % 0.05 % 10.63 % 4.93 %
EPS Net 5 Year Avg. Change 8.27 % 14.16 % 9.09 % 23.95 %



Abbott Laboratories's EPS were sliced by -43.62% in the third quarter from the same quarter a year ago, to $ 0.53, while income per share in Major Pharmaceutical Preparations industry fell only by -31.6%, and underperformed the -39.2% EPS slide in the Healthcare sector. Weak third quarter income per share, in Major Pharmaceutical Preparations industry and within the Healthcare sector, were reflected in Abbott Laboratories results which underperformed overall market.

Sequentially company's EPS were unchanged from the second quarter results. . Looking into annual growth, income per share grew by 8.27% on average in the last five years, while the S & P 500's including only the businesses with the third quarter 2026 financial results, average yearly income per share growth is 23.95%.

ABT Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) -46.57 % 25.56 % 44.26 % 48.62 %
Sequential Free Cash Flow Change (Q3 MRQ) -38.52 % -29.98 % -42.65 % 34.18 %
Y / Y Free Cash Flow Change (Q3 TTM) -2.31 % 12.44 % 19.33 % 60.27 %
Sequential Free Cash Flow Change (Q3 TTM) -13.64 % 3.57 % 5.88 % 15.75 %
Free Cash Flow 5 Year Avg. Change 5.26 % 0.88 % 0.41 % 1.79 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q3 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q3 TTM) - - - 209.43 %
Sequential Net Cash Flow Change (Q3 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change -21.18 % 29.88 % 6.46 % 1.07 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) 3.43 % 18.43 % 10.33 % 120.03 %
Sequential Capital Expenditures Change (Q3 MRQ) 3.22 % -21.14 % -19.32 % 36.87 %
Y / Y Capital Expenditures Change (Q3 TTM) -4.72 % 15.58 % 9.34 % 109.38 %
Sequential Capital Expenditures Change (Q3 TTM) 0.82 % 1.87 % 0.99 % 23.05 %
Capital Expenditures 5 Year Avg. Change -0.06 % 7.84 % 8.61 % 14.19 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.